Agilent Technologies’ Exome Target-Enrichment System to Analyze 1,500 Samples in Erasmus Genetic Population Study
Published: Thursday, March 08, 2012 Last Updated: Thursday, March 08, 2012
Erasmus Medical Center, Rotterdam, Netherlands, has selected the Agilent SureSelect XT Human All Exon target enrichment system along with the Agilent Bravo automated liquid-handling platform as part to identify genetic risk factors for some complex genetic disorders.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.